A polymorphism in the cystatin C gene is a novel risk factor for late-onset Alzheimer’s disease

Objective: To investigate whether or not a coding polymorphism in the cystatin C gene (CST3) contributes risk for AD. Design: A case-control genetic association study of a Caucasian dataset of 309 clinic- and community-based cases and 134 community-based controls. Results: The authors find a signficant interaction between the GG genotype of CST3 and age/age of onset on risk for AD, such that in the over-80 age group the GG genotype contributes two-fold increased risk for the disease. The authors also see a trend toward interaction between APOE ε4-carrying genotype and age/age of onset in this dataset, but in the case of APOE the risk decreases with age. Analysis of only the community-based cases versus controls reveals a significant three-way interaction between APOE, CST3 and age/age of onset. Conclusion: The reduced or absent risk for AD conferred by APOE in older populations has been well reported in the literature, prompting the suggestion that additional genetic risk factors confer risk for later-onset AD. In the author’s dataset the opposite effects of APOE and CST3 genotype on risk for AD with increasing age suggest that CST3 is one of the risk factors for later-onset AD. Although the functional significance of this coding polymorphism has not yet been reported, several hypotheses can be proposed as to how variation in an amyloidogenic cysteine protease inhibitor may have pathologic consequences for AD.

[1]  K. Isoe,et al.  Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia , 1996, Acta neurologica Scandinavica.

[2]  D. Graham,et al.  The Apolipoprotein E ∈2 Allele and the Pathological Features in Cerebral Amyloid Angiopathy-related Hemorrhage , 1999 .

[3]  N. Craddock,et al.  Genetic association studies between dementia of the Alzheimer's type and three receptors for apolipoprotein E in a Caucasian population , 1997, Neuroscience Letters.

[4]  M. Owen,et al.  Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease , 1999, Nature Genetics.

[5]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[6]  A. Smith,et al.  Synergy between the genes for butyrylcholinesterase K variant and apolipoprotein E4 in late-onset confirmed Alzheimer's disease. , 1997, Human molecular genetics.

[7]  M. Owen,et al.  The butyrylcholinesterase K variant and susceptibility to Alzheimer's disease. , 1998, Journal of medical genetics.

[8]  G. Gudmundsson,et al.  On the role of monocytes/macrophages in the pathogenesis of central nervous system lesions in hereditary cystatin C amyloid angiopathy , 1992, Journal of the Neurological Sciences.

[9]  N. Bornstein,et al.  APOE-ε4 in Patients with Alzheimer Disease and Vascular Dementia , 1996 .

[10]  K. Nakashima,et al.  Apolipoprotein E Polymorphism in Patients with Alzheimer’s Disease, Vascular Dementia and Ischemic Cerebrovascular Disease , 1998, Dementia and Geriatric Cognitive Disorders.

[11]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[12]  M. Manfredi,et al.  The prevalence of apoE-ε4 in Alzheimer’s disease is age dependent , 1998 .

[13]  S. DeKosky,et al.  APOE*4-associated Alzheimer's disease risk is modified by alpha 1-antichymotrypsin polymorphism. , 1995, Nature genetics.

[14]  Bonnie F. Sloane,et al.  Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells. , 1998, Molecular pathology : MP.

[15]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[16]  I. Kanazawa,et al.  Genetic association of the very low density lipoprotein (VLDL) receptor gene with sporadic Alzheimer's disease , 1995, Nature Genetics.

[17]  M. Gold,et al.  No genetic association between polymorphisms in the Tau gene and Alzheimer's disease in clinic or population based samples , 1999, Neuroscience Letters.

[18]  Vascular factors and Alzheimer disease. , 1999, Alzheimer disease and associated disorders.

[19]  R. Roos,et al.  Co‐localization of β/A4 and cystatin C in cortical blood vessels in Dutch, but not in Icelandic hereditary cerebral hemorrhage with amyloidosis , 1994, Acta neurologica Scandinavica.

[20]  A. Hofman,et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study , 1997, The Lancet.

[21]  R N Kalaria,et al.  Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. , 1996, The American journal of pathology.

[22]  D. Sparks.  Coronary Artery Disease, Hypertension, ApoE, and Cholesterol: A Link to Alzheimer's Disease? , 1997, Annals of the New York Academy of Sciences.

[23]  Miguel Ángel Martínez,et al.  Apolipoprotein E and Alzheimer disease: genotype-specific risks by age and sex. , 1997, American journal of human genetics.

[24]  H. Vinters,et al.  Microvascular degeneration in hereditary cystatin C amyloid angiopathy of the brain , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[25]  L. Thal,et al.  Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease , 1996, Neurology.

[26]  S. McIlroy,et al.  Butyrylcholinesterase K variant is genetically associated with late onset Alzheimer's disease in Northern Ireland , 2000, Journal of medical genetics.

[27]  J. Haines,et al.  ApoE-4 and Age at Onset of Alzheimer's Disease , 1997, Neurology.

[28]  D. Graham,et al.  The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage. , 1999, Journal of neuropathology and experimental neurology.

[29]  N. Bornstein,et al.  APOE-epsilon 4 in patients with Alzheimer disease and vascular dementia. , 1996, Alzheimer disease and associated disorders.

[30]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[31]  G C Roman,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[32]  PhilipR. Wenham,et al.  Apolipoprotein E genotyping by one-stage PCR , 1991, The Lancet.

[33]  R. Duara,et al.  The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations , 1998, Neuroscience Letters.

[34]  C. Jagger,et al.  Factors associated with vascular dementia in an elderly community population , 1999, International journal of geriatric psychiatry.

[35]  F. Fazekas,et al.  Vascular risk factors in dementia , 2000, Journal of Neurology.

[36]  B. Frangione,et al.  Hereditary cystatin C (γ‐trace) amyloid angiopathy of the CNS causing cerebral hemorrhage , 1987 .

[37]  G. Breen,et al.  Association between Alzheimer's disease and the NOS3 gene , 1999, Annals of neurology.

[38]  K. Davis,et al.  The relationship between apolipoprotein E, dementia, and vascular illness. , 1998, Atherosclerosis.

[39]  A. Hofman,et al.  Apolipoprotein E epsilon4 and the risk of dementia with stroke. A population-based investigation. , 1997, JAMA.

[40]  W. Tsai,et al.  Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. , 1996, American journal of human genetics.

[41]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[42]  The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent. , 1998, Journal of neurology, neurosurgery, and psychiatry.

[43]  A. Hofman,et al.  Dietary fat intake and the risk of incident dementia in the Rotterdam study , 1997, Annals of neurology.

[44]  H. Wiśniewski,et al.  Cellular processing of the amyloidogenic cystatin C variant of hereditary cerebral hemorrhage with amyloidosis, Icelandic type. , 1999, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[45]  B. Winblad,et al.  Aging and the occurrence of dementia: findings from a population-based cohort with a large sample of nonagenarians. , 1999, Archives of neurology.

[46]  C. López-Otín,et al.  Stroke in Icelandic patients with hereditary amyloid angiopathy is related to a mutation in the cystatin C gene, an inhibitor of cysteine proteases , 1989, The Journal of experimental medicine.

[47]  G. Gudmundsson,et al.  Hereditary cystatin C (gamma-trace) amyloid angiopathy of the CNS causing cerebral hemorrhage. , 1987, Acta neurologica Scandinavica.

[48]  M. Ilyas Kamboh,et al.  A4POE*4-associated Alzheimer's disease risk is modified by α1–antichymotrypsin polymorphism , 1995, Nature Genetics.

[49]  R. Duara,et al.  Gender-specific association of the angiotensin converting enzyme gene with Alzheimer's disease , 2000, Neuroscience Letters.

[50]  H. Vinters,et al.  Immunoreactive A4 and gamma-trace peptide colocalization in amyloidotic arteriolar lesions in brains of patients with Alzheimer's disease. , 1990, The American journal of pathology.